DUARTE, Calif., July 29, 2015 — Medical oncologist and lung cancer researcher Karen Reckamp, M.D., M.S., has been named Medical Director for Clinical Research Operations at City of Hope.
In this newly created position, Reckamp will expand her current role as chair of the Cancer Protocol Review and Monitoring Committee, in which she has been instrumental in supporting and shaping the regulatory, operational and scientific directives of the clinical research mission of City of Hope. As medical director, she’ll serve as medical advisor for Clinical Research Operations, as medical director of the Clinical Trials Unit and as coordinating liaison for pharmaceutical contracts. She will also share responsibility for the review and selection of clinical trials within City of Hope.
“Karen has shown remarkable leadership as City of Hope moves to launch a new era of scientific research and life-saving clinical trials,” said Larry W. Kwak, M.D., Ph.D., associate director for developmental therapeutics and translational research at City of Hope and director of the Toni Stephenson Lymphoma Center. “Her deep knowledge of the complex regulatory and operational aspects of City of Hope’s clinical trials has been, and will continue to be, invaluable as we rapidly turn breakthrough research into new treatments and cures.”
Nationally known for her clinical research expertise, Reckamp is also co-chair of the institution’s Lung Cancer and Thoracic Oncology Program and has helped expand options for people diagnosed with lung cancer. She is currently principal investigator for an arm of the National Cancer Institute’s NCI-Molecular Analysis for Therapy Choice, known as the NCI-MATCH trial.
Reckamp joined City of Hope in 2007, as assistant professor of medicine in the Department of Medical Oncology & Therapeutics. In 2012, she became associate professor in the Department of Medical Oncology & Therapeutics Research and co-director of the Lung Cancer and Thoracic Oncology Program at City of Hope.
She received her medical doctorate from the University of Chicago, Pritzker School of Medicine, and her master’s of science degree from the University of California, Los Angeles, where she also received specialized training in advanced research and clinical research. She completed a fellowship in hematology/oncology at UCLA, and an internship and residency at Barnes-Jewish Hospital in St. Louis. She is board-certified in internal medicine, hematology and oncology.
Her research has been funded by the National Cancer Institute, the Lung Cancer Research Foundation, the Department of Defense and STOP CANCER. Over her career, Reckamp has delivered more than 160 presentations and published more than 150 peer-reviewed papers, book chapters and abstracts.
About City of Hope
City of Hope is an independent research and treatment center for cancer, diabetes and other life-threatening diseases. Designated as a comprehensive cancer center, the highest recognition bestowed by the National Cancer Institute, City of Hope is also a founding member of the National Comprehensive Cancer Network, with research and treatment protocols that advance care throughout the nation. City of Hope’s main hospital is located in Duarte, California, just northeast of Los Angeles, with clinics in Southern California. It is ranked as one of "America's Best Hospitals" in cancer by U.S. News & World Report. Founded in 1913, City of Hope is a pioneer in the fields of bone marrow transplantation and genetics.